Alterity Therapeutics Limited ATHE
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -31.16% | 12.94% | 73.75% | 51.65% | 32.42% |
| Total Revenue | -31.16% | 12.94% | 73.75% | 51.65% | 32.42% |
| Cost of Revenue | 117.68% | 40.97% | -11.74% | -28.11% | -41.25% |
| Gross Profit | -34.77% | 11.94% | 78.11% | 55.94% | 36.57% |
| SG&A Expenses | 100.67% | 57.66% | 19.23% | 16.00% | 14.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 235.63% | 252.95% | 278.07% | 375.83% | 1,567.65% |
| Total Operating Expenses | 50.38% | 21.42% | -2.27% | -9.67% | -16.26% |
| Operating Income | -80.35% | -23.60% | 16.07% | 21.50% | 26.23% |
| Income Before Tax | -102.55% | -20.89% | 28.00% | 33.02% | 37.32% |
| Income Tax Expenses | 77.96% | 119.45% | 174.34% | 107.89% | 41.78% |
| Earnings from Continuing Operations | -102.42% | -21.24% | 27.53% | 32.68% | 37.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -102.42% | -21.24% | 27.53% | 32.68% | 37.13% |
| EBIT | -80.35% | -23.60% | 16.07% | 21.50% | 26.23% |
| EBITDA | -80.68% | -23.77% | 15.99% | 21.47% | 26.24% |
| EPS Basic | -14.92% | 35.26% | 60.32% | 61.37% | 61.74% |
| Normalized Basic EPS | -0.64% | 33.85% | 53.49% | 55.45% | 56.45% |
| EPS Diluted | -14.24% | 35.66% | 60.83% | 61.07% | 60.75% |
| Normalized Diluted EPS | -0.64% | 33.85% | 53.49% | 55.45% | 56.45% |
| Average Basic Shares Outstanding | 64.53% | 69.02% | 74.72% | 74.97% | 75.31% |
| Average Diluted Shares Outstanding | 64.53% | 69.02% | 74.72% | 74.97% | 75.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |